Gastroesophageal Reflux Disease

Colin W. Howden, MD
Professor of Medicine, Division of Gastroenterology, Northwestern University, Feinberg School of Medicine, Chicago, IL

William D. Chey, MD
Associate Professor, Division of Gastroenterology, Director of the GI Physiology Laboratory, University of Michigan Health System, Ann Arbor, MI

**PRACTICE RECOMMENDATIONS**

- Heartburn on 2 or more days a week warrants medical attention, as patients are likely to suffer from gastroesophageal reflux disease (GERD). Chronic GERD can lead to the development of complications including erosive esophagitis, stricture formation, and Barrett’s esophagus, which increases the risk of esophageal adenocarcinoma.
- A trial with a proton pump inhibitor (PPI) is the quickest and most cost-effective way to diagnose GERD, and is at least as sensitive as 24-hour intragastric pH monitoring.
- As PPIs only bind to actively secreting proton pumps, they should be dosed 30 to 60 minutes before a meal. Despite these recommendations, a recent survey of over 1000 US primary care physicians found that 36% instructed their patients to take a PPI with or after a meal or did not specify the timing of dosing.
- The patients who will have the best response to surgical therapy for GERD are those who had clearly documented acid reflux with typical symptoms, and who have responded to PPI treatment. Unfortunately, the same survey found that most physicians recommend antireflux surgery for patients in whom medical therapy has failed.

**SYMPTOMS OF GERD**

The typical symptoms of GERD are heartburn and regurgitation. Heartburn is best defined as a burning retrosternal discomfort starting in the epigastrium or lower chest and moving upwards towards the neck.
Regurgitation is the effortless movement of gastric contents up into the esophagus or pharynx.

Most patients with GERD do not have endoscopically visible lesions; a careful analysis of symptoms generally forms the basis of a preliminary diagnosis.

The occurrence of heartburn on 2 or more days a week has been suggested as a basis for further investigation for GERD. However, symptoms vary greatly. Patients may be asymptomatic or experience symptoms that more closely resemble gastric disorders, infectious and motor disorders of the esophagus, biliary tract disease, or even coronary artery disease.

Extraesophageal manifestations
Adding to the complexity of diagnosis, GERD has been shown to have extraesophageal manifestations, including chronic cough, asthma, recurrent aspiration, chronic sore throat, reflux laryngitis, and paroxysmal laryngospasm or voice changes.

Although the relationship between asthma and GERD remains unclear, it has been estimated that 24% to 98% of patients with asthma also have GERD. Some patients with asthma have been shown to have excess acid reflux into the esophagus. Reflux-like symptoms may precede episodes of asthma that occur after meals or when lying down.

Additionally, GERD has been noted in 10% to 50% of patients with non-cardiac chest pain.
**Clinical UPDATE**

**DIAGNOSTIC STRATEGIES**

**Trial of treatment**

Diagnosis is usually based on typical symptoms—heartburn or regurgitation—in the clinical history. (The Figure shows a treatment algorithm for both severe and mild symptoms.)

A 2-week trial of treatment with a proton pump inhibitor (PPI) provides the quickest and most cost-effective confirmation of diagnosis and is recommended for the patient whose history suggests uncomplicated GERD. A positive response to PPI treatment in a patient with symptoms suggestive of GERD is at least as sensitive and specific as 24-hour intraesophageal pH monitoring, which is still often considered the “gold standard” for the diagnosis of GERD. Furthermore, complete lack of improvement in response to PPI treatment is highly predictive that the patient does not have GERD and indicates the need for further evaluation and a possible revision of diagnosis.11,12

H₂ receptor antagonists (H₂RAs) have also been investigated in empirical trials for usefulness in diagnosing GERD. H₂RAs are less effective than PPIs.13,14

**Endoscopy**

No data support routine endoscopy for patients with the recent onset of uncomplicated heartburn who respond to medical therapy. Endoscopy is recommended, however, for patients with severe or atypical GERD symptoms, when other diseases may be present, or when a treatment trial with a PPI is ineffective.15 Endoscopy is useful for diagnosing complications of GERD, such as Barrett’s esophagus, esophagitis, and strictures. Fewer than 50% of patients with GERD symptoms have evidence of esophagitis on endoscopy.16 The American Society for Gastrointestinal Endoscopy recommends endoscopy when there are clinical suggestions of severe reflux or other disease.17 The American College of Gastroenterology recommends further testing

- when empiric therapy has failed
- when symptoms of complicated disease exist
- when there is dysphagia, bleeding, weight loss, choking, chest pain, or long-standing symptoms

**TABLE 1**

<table>
<thead>
<tr>
<th>Over-the-counter therapy for GERD</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Prevention and rapid relief of symptoms</td>
</tr>
<tr>
<td>• Reduction of frequency and severity of symptoms</td>
</tr>
<tr>
<td>• Role in therapy</td>
</tr>
<tr>
<td>• Primary treatment (approved indication, evidence-based)</td>
</tr>
<tr>
<td>• Breakthrough symptoms in patients taking PPIs (no evidence)</td>
</tr>
<tr>
<td>• Limitations</td>
</tr>
<tr>
<td>• 60%–70% efficacy for above</td>
</tr>
<tr>
<td>• Unclear role in erosive esophagitis</td>
</tr>
<tr>
<td>• Approved and tested for short-term use (2–4 weeks)</td>
</tr>
</tbody>
</table>


- when continuous therapy is required
- to screen for Barrett’s esophagus.18

The Canadian Consensus Conference recommends endoscopy in the presence of

- dysphagia
- odynophagia
- bleeding
- weight loss
- noncardiac chest pain
- failure to respond to 4 to 8 weeks of pharmacologic therapy.19

It also recommends a single test if maintenance therapy is required.

**Other diagnostic tests**

Other diagnostic tools may be of use in some settings.

A barium esophagram can docu-
ment reflux, and Bernstein testing (esophageal acid infusion test) can identify esophageal hypersensitivity to acid, although neither establishes a diagnosis of GERD. Ambulatory 24-hour intraesophageal pH monitoring can help to establish the presence of GERD by documenting the proportion of time during which the intraesophageal pH is acidic (<4) and can also establish the degree of association between patients’ symptoms and episodes of esophageal acidification.

Esophageal manometry is not recommended as a routine diagnostic test for GERD. It is important in selected patients to exclude an esophageal motility disorder and may be necessary as part of the preoperative evaluation for patients in whom a surgical operation for GERD is being considered.

**MANAGEMENT OF GERD**

GERD commonly requires long-term management that includes dietary, lifestyle, and pharmacological interventions. Surgery may be considered for the long-term management of the condition in carefully selected patients.

**Diet and lifestyle**

**Dietary modifications.** Patients should not consume large meals and should avoid lying down for 3 to 4 hours after eating. Caffeinated products, peppermint, fatty foods, chocolate, spicy foods, citrus fruits and juices, tomato-based products, and alcohol may contribute to episodes of GERD. Lozenges of any kind are able to stimulate salivary secretion, help clear refluxed acid, and hence, help relieve symptoms.

**Lifestyle modifications.** Changes in lifestyle may include such seemingly sensible interventions as sleeping with the head elevated, stopping smoking, and losing weight. There is little or no established evidence for the efficacy of these and other lifestyle modifications in the management of GERD. However, in

---

**TABLE 2**

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Step-down therapy</strong></td>
<td>Rapid symptom relief</td>
<td>Potential overtreatment</td>
</tr>
<tr>
<td>(high-dose initial therapy)</td>
<td>Efficient for physician</td>
<td>Higher initial drug cost</td>
</tr>
<tr>
<td></td>
<td>Avoids overinvestigation and associated costs</td>
<td></td>
</tr>
<tr>
<td><strong>Step-up therapy</strong></td>
<td>Avoids overtreatment</td>
<td>Patient may continue with symptoms unnecessarily</td>
</tr>
<tr>
<td>(minimum-dose initial therapy)</td>
<td>Lower initial drug cost</td>
<td>Inefficient for physician</td>
</tr>
<tr>
<td></td>
<td></td>
<td>May lead to overinvestigation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Uncertain end point (partial symptom relief)</td>
</tr>
</tbody>
</table>
1 trial of 63 patients, elevating the head of the bed with 6-inch blocks resulted in 1 less episode of heartburn or acid regurgitation per night when compared with lying flat. In another trial of 71 patients with esophagitis, elevating the bed was nearly as effective as ranitidine for reducing symptoms and producing endoscopically verifiable healing.

**Drug interventions**

Pharmacological interventions include over-the-counter remedies such as antacids and H₂RAs (Table 1), as well as prescription-only doses of H₂RAs and PPIs. At the time of writing, no PPI was available in an over-the-counter preparation in the United States, although over-the-counter omeprazole may soon be approved. Many authorities believe an incremental approach to the management of GERD is appropriate, beginning with lifestyle modifications and over-the-counter preparations, continuing with H₂ blockers, and reserving PPIs for nonresponders. While this approach may have appeal from a cost perspective, we believe another approach (as illustrated in the Figure) is clinically superior.

**Antacids.** Over-the-counter antacids rapidly increase the pH of the intraesophageal contents and also neutralize acidic gastric contents that might be refluxed. They are frequently used to treat heartburn. However, few clinical trials have evaluated the efficacy of antacids. Published trials are limited by small sample sizes and a lack of intention-to-treat analysis. Only one showed positive evidence for antacid efficacy.

The utility of antacids is limited by the need for frequent dosing and possible interactions with such...
drugs as fluoroquinolones, tetracycline, and ferrous sulfate.\(^{27}\)

Alginate/antacids have shown statistically significant benefit compared with placebo for relief of mild-to-moderate GERD symptoms and healing of esophagitis.\(^{24,28-34}\)

**\(H_2\) receptor antagonists.** \(H_2\)RAs have shown positive effects on symptoms in some studies, although symptomatic response rates observed were only around 60% to 70%. Additionally, most of the trials to date have been for 2 to 6 weeks in duration.\(^{35-43}\) An issue worthy of consideration with the \(H_2\)RAs is the development of tolerance with continuous use.\(^{44}\)

An \(H_2\)RA-antacid combination was recently evaluated in a trial that compared it with monotherapy using either agent. Of the patients receiving combination therapy, 81% reported an excellent or good symptom response. Those receiving famotidine or atacid alone reported a 72% excellent or good symptom response.\(^{3}\)

**Proton pump inhibitors.** PPIs potently reduce gastric acid secretion by inhibiting the \(H^+\)K\(^+\) adenosine triphosphatase pump of the parietal cell. As a result, they suppress gastric acid secretion for a longer period than \(H_2\)RAs.\(^{45}\) Evidence from randomized, controlled trials has demonstrated the superiority of PPIs over any other class of drugs for the relief of GERD symptoms, for healing esophagitis, and for maintaining patients in remission. Standard doses of omeprazole, lansoprazole, pantoprazole, esomeprazole, and rabeprazole have, for the most part, shown comparable rates of healing and remission in erosive esophagitis.\(^{46-52}\)

PPIs are best absorbed in the absence of food. Ingestion of food after a PPI stimulates parietal cell activity when blood levels of the PPI are increasing; this promotes uptake of the PPI by the parietal cells. Therefore, patients should be advised to take their PPI between 30 and 60 minutes before eating. For patients on a once-daily PPI, the best time to take it is about 30 to 60 minutes before breakfast. For patients on a once-daily PPI, the best time to take it is about 30 to 60 minutes before breakfast. Despite these recommendations, a recent survey of over 1000 US primary care physicians found that 36% instructed their patients to take their PPI with or after a meal or did not specify the timing of dosing.\(^{53}\)

PPI therapy can be tailored to control GERD symptoms. Treatment can start with the most effective dosage and then be stepped down, or start with a minimum dosage and then be stepped up (Table 2). Patients with predominantly daytime symptoms should take PPIs before breakfast. Concerns that were once expressed about the long-term use of PPIs, such as predisposing patients to stomach cancer, have been refuted by extensive clinical experience and intensive monitoring (Table 3).\(^{3}\)

**Surgery**

Surgical antireflux therapy is an option in carefully selected patients. Those who respond best to surgical therapy will have had clearly documented acid reflux, typical symptoms, and symptomatic improvement while on PPI treatment.\(^{54}\)

Unfortunately, a recent survey suggests that physicians tend to recommend surgery for patients in whom medical therapy has failed.\(^{53}\)
However, patients who failed to respond to PPI therapy are unlikely to have GERD and, therefore, are highly unlikely to have a good outcome from antireflux surgery. Recent studies suggest that up to 62% of patients who have had open surgery for GERD continue to require medical treatment afterward. Although some studies demonstrate that surgery has greater efficacy over medical therapy initially, long-term follow-up has shown that surgically treated patients often need further medical therapy for persistent GERD symptoms. Community-based studies of antireflux surgery indicate that many patients develop new symptoms that they did not have before surgery and that these substantially diminish quality of life.

New endoscopic therapies, including radiofrequency energy delivery to the region of the lower esophageal sphincter and endoscopic suturing, have recently been approved for use by the FDA. This approval was based largely on safety rather than efficacy. Clinical evidence is limited to uncontrolled studies in patients with no or mild esophagitis. These techniques should not be used in preference to established medical treatment unless and until data from randomized, controlled trials become available that demonstrate safety and efficacy.

REFERENCES


40. Ciociola AA, Pappa KA, Sirgo MA. Nonprescription doses of ranitidine are effective in the relief of episodic heartburn. Am J Ther 2001; 8:399–408.


